CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.
—
CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.
—
Daily adjusted close
CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.